Youngen, based in Beijing, is a biotechnology company pioneering the development of next-generation siRNA drugs to silence specific mRNAs and reduce the production of proteins that cause disease. Youngen has been dedicating to bring RNAi therapeutics to a broad spectrum of difficult-to-treat diseases, both rare and general population impacting millions of people around the world. Leveraging these platform technologies, we built diversified product pipelines with globally competitive, first-in-class and best-in-class potential. We’re exploring many therapeutic areas to bring more treatment options to the patients with metabolic and cardiovascular diseases, immune-mediated diseases, and neurological disorders.